Want to see IMUX full AI Analyst Report?
IMUX Stock Chart & Stats
$16.49
$0.34(2.54%)
At close: 4:00 PM EDT
$16.49
$0.34(2.54%)
Day’s Range― - ―
52-Week Range$5.06 - $17.43
Previous CloseN/A
Volume44.90K
Average Volume (3M)414.27K
Market Cap
$95.37M
Enterprise Value$498.91M
Total Cash (Recent Filing)$155.10M
Total Debt (Recent Filing)$567.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Oct 29, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.80
Shares Outstanding13,644,467
10 Day Avg. Volume413,581
30 Day Avg. Volume414,275
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market Cap5.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.12K
Enterprise Value/Ebitda-4.48
Forecast
1Y Price Target
$37.38Price Target Upside126.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt gives Immunic greater financial flexibility than a highly leveraged biotech and limits interest-related pressure on cash. Although losses remain substantial, the low debt burden could help management direct available capital toward clinical development and other operating priorities.
Potentially Broad MS PipelineThe lead program is being developed across relapsing and progressive multiple sclerosis, creating the possibility of a broader franchise if clinical results support expansion. Advancement into additional pivotal studies could increase the strategic value of the pipeline over the next several quarters.
Stronger Strategic OversightAdding a director with extensive biopharmaceutical finance, capital-markets and corporate-development experience strengthens oversight during pivotal clinical and potential commercialization milestones. This expertise may improve strategic planning and capital allocation as Immunic approaches major program decisions.
Bears Say
No Commercial RevenueImmunic has not yet established product revenue, so its ability to fund operations depends on advancing candidates toward approval and eventual commercialization. Until that occurs, the company lacks an operating revenue base to offset research, development and corporate expenses.
High Cash BurnPersistent negative operating and free cash flow indicate that Immunic is consuming substantial capital while its programs remain in development. Continued spending at this level can reduce financial flexibility and keep the company reliant on external financing until revenue or spending discipline changes.
Clinical And Regulatory Execution RiskThe pipeline’s future value depends on successful clinical outcomes, regulatory progress and adequate financing, all of which management identified as material uncertainties. Failure in any of these areas could delay development, increase funding needs or limit the commercial potential of vidofludimus calcium.
Immunic News
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $5.06 and its highest was $17.43 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $95.37M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Aug 11, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.165 by $0.365.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.94.
How many shares outstanding does Immunic have?
Immunic has 13,644,467 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.165. Following the earnings report the stock price went up 9.787%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.38 (126.65% Upside)
$37.38 (126.65% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 371.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.65%
12-Months-Change
Fundamentals
Return on Equity
-157.89%
Trailing 12-Months
Asset Growth
159.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunic
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$37.38
▲(126.65% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
12.38%
Insiders
8.48% Mutual Funds
37.85% Other Institutional Investors
36.35% Public Companies and
Individual Investors